@article{JTD5498,
author = {Ji’e Yang and Wahafu Mamuti and Feng Zhang},
title = {Optimal interventional strategy for the treatment of coronary in-stent restenosis},
journal = {Journal of Thoracic Disease},
volume = {7},
number = {10},
year = {2015},
keywords = {},
abstract = {In-stent restenosis (ISR) has been an important issue in the era of percutaneous coronary intervention (PCI) since the first bare metal stent (BMS) was applied to clinical settings. BMS substantially reduces acute vessel closure and restenosis after PCI by attenuating early arterial recoil and contraction, two major limitations of plain old balloon angioplasty (POBA). Thereby, it has been considered as a major advancement over POBA. However, ISR caused by neointimal hyperplasia after stent implantation hampers the benefit of BMS by increasing the rate of target lesion revascularization (TLR) or target vessel revascularization (TVR). With the innovation of stent technology, drug-eluting stents (DES) designed to inhibit excessive neointimal growth was produced and anticipated to reduce the incidence of ISR. Indeed, the RAVEL trial (1), a double-blind randomized study comparing sirolimus-eluting stent with its non-coated counterpart, reported no restenosis in the sirolimus stent group, and 23.4% of the patient in the BMS group developed binary restenosis (P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/5498}
}